Freeline: Funding, Investors & Team (Oct 2026)
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.
Freeline has raised $26.1M across 1 funding round on record, the most recent a Post-IPO Equity of $26.1M announced in Mar 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Freeline Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Freeline Funding Rounds
Freeline Founders and Leadership Team
Contact details for the Freeline team: 1 of 1 has an email address on file.
Start 14-day free trial →Freeline Funding Compared to Other Biotechnology Startups
Freeline's latest round of $26.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Freeline in Biotechnology and Stevenage
Companies Similar to Freeline
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Freeline Funding FAQs
What does Freeline do?
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.
How much funding has Freeline raised?
Freeline has raised $26.1M across 1 round on record. The most recent is a Post-IPO Equity of $26.1M announced in Mar 2022.
When did Freeline last raise funding?
Freeline's most recent funding round on record is a Post-IPO Equity of $26.1M, announced in Mar 2022.
Who founded Freeline?
FundedIQ lists Amit Nathwani (Founder & Chief Scientific Officer) at Freeline.
Where is Freeline headquartered?
Freeline is based in Stevenage, Herefordshire, United Kingdom.
How many employees does Freeline have?
Freeline is in the 101-250 employee band.
How does Freeline's funding compare to other Biotechnology startups?
Freeline's latest round of $26.1M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Freeline Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Freeline is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.